Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis
- 1k Downloads
Among a variety of phytocannabinoids, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most promising therapeutic compounds. Besides the well-known palliative effects in cancer patients, cannabinoids have been shown to inhibit in vitro growth of tumor cells. Likewise, the major endocannabinoids (eCBs), anandamide (AEA) and 2-arachidonoylglycerol (2-AG), induce tumor cell death. The purpose of the present study was to characterize cannabinoid elements and evaluate the effect of cannabinoids in endometrial cancer cell viability. The presence of cannabinoid receptors, transient receptor potential vanilloid 1 (TRPV1), and endocannabinoid-metabolizing enzymes were determined by qRT-PCR and Western blot. We also examined the effects and the underlying mechanisms induced by eCBs and phytocannabinoids in endometrial cancer cell viability. Besides TRPV1, both EC cell lines express all the constituents of the endocannabinoid system. We observed that at concentrations higher than 5 μM, eCBs and CBD induced a significant reduction in cell viability in both Ishikawa and Hec50co cells, whereas THC did not cause any effect. In Ishikawa cells, contrary to Hec50co, treatment with AEA and CBD resulted in an increase in the levels of activated caspase −3/−7, in cleaved PARP, and in reactive oxygen species generation, confirming that the reduction in cell viability observed in the MTT assay was caused by the activation of the apoptotic pathway. Finally, these effects were dependent on TRPV1 activation and intracellular calcium levels. These data indicate that cannabinoids modulate endometrial cancer cell death. Selective targeting of TPRV1 by AEA, CBD, or other stable analogues may be an attractive research area for the treatment of estrogen-dependent endometrial carcinoma. Our data further support the evaluation of CBD and CBD-rich extracts for the potential treatment of endometrial cancer, particularly, that has become non-responsive to common therapies.
KeywordsEndocannabinoids Phytocannabinoids Endometrial cancer Apoptosis
Cannabinoid receptor 1
Cannabinoid receptor 2
Fatty acid amide hydrolase
The authors are grateful for the financial support under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF), UID/MULTI/04378/2013-POCI/01/0145/FEDER/007728 from FCT/MEC through national funds and co-financed by FEDER - Portugal, under the Partnership Agreement PT2020, NORTE-01-0145-FEDER-000024.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Anzai Y, Gong YW, Holinka CF, Murphy LJ, Murphy LC, Kuramoto H, Gurpide E (1992) Effects of transforming growth-factors and regulation of their messenger-Rna levels in 2 human endometrial adenocarcinoma cell-lines. J Steroid Biochem Mol Biol 42:449–455. https://doi.org/10.1016/0960-0760(92)90256-I CrossRefPubMedGoogle Scholar
- 10.Contassot E, Wilmotte R, Tenan M, Belkouch MC, Schnuriger V, De Tribolet N, Bourkhardt K, Dietrich PY (2004) Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J Neuropath Exp Neur 63(9):956–963. https://doi.org/10.1093/jnen/63.9.956 CrossRefPubMedGoogle Scholar
- 14.Fonseca BM, Costa MA, Almada M, Correia-da-Silva G, Teixeira NA (2013) Endogenous cannabinoids revisited: a biochemistry perspective. Prostaglandins Other Lipid Mediat 102–103:13–30. https://doi.org/10.1016/j.prostaglandins.2013.02.002 CrossRefPubMedGoogle Scholar
- 15.Galve-Roperh I, Sanchez C, Cortes ML, Gomez del Pulgar T, Izquierdo M, Guzman M (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6(3):313–319. https://doi.org/10.1038/73171 CrossRefPubMedGoogle Scholar
- 16.Guida M, Ligresti A, De Filippis D, D'Amico A, Petrosino S, Cipriano M, Bifulco G, Simonetti S, Orlando P, Insabato L, Nappi C, Di Spiezio Sardo A, Di Marzo V, Iuvone T (2010) The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. Endocrinology 151(3):921–928. https://doi.org/10.1210/en.2009-0883 CrossRefPubMedGoogle Scholar
- 19.Iannotti FA, Hill CL, Leo A, Alhusaini A, Soubrane C, Mazzarella E, Russo E, Whalley BJ, Di Marzo V, Stephens GJ (2014) Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci 5(11):1131–1141. https://doi.org/10.1021/cn5000524 CrossRefPubMedGoogle Scholar
- 21.Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, Di Marzo V (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318(3):1375–1387. https://doi.org/10.1124/jpet.106.105247 CrossRefPubMedGoogle Scholar
- 23.Maccarrone M, Bab R, Biro T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A (2015) Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 36(5):277–296. https://doi.org/10.1016/j.tips.2015.02.008 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Nishida M (2002) The Ishikawa cells from birth to the present. Hum Cell 15(3):104–117. https://doi.org/10.1111/j.1749-0774.2002.tb00105.x CrossRefPubMedGoogle Scholar
- 31.Taylor AH, Abbas MS, Habiba MA, Konje JC (2010) Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle. Histochem Cell Biol 133(5):557–565. https://doi.org/10.1007/s00418-010-0695-9 CrossRefPubMedGoogle Scholar